Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors

Clinical Cancer Research

Volumn 11, Issue 8, 2005, Pages 3117-3125

  Flessner, Michael F ^a   Choi, Jaewah ^a   Credit, Kimberly ^a   Deverkadra, Ravi ^a   Henderson, Karla ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; PACLITAXEL; PROSTAGLANDIN E1; TRASTUZUMAB;

ABDOMINAL WALL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG PENETRATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; OVARY METASTASIS; PRESSURE GRADIENT; PRIORITY JOURNAL; RAT; RAT STRAIN; RECEPTOR BINDING; THERMODYNAMICS; TISSUE PRESSURE; TUMOR BLOOD FLOW; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD CIRCULATION; CELL LINE, TUMOR; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; IODINE RADIOISOTOPES; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PERITONEUM; PRESSURE; RATS; RATS, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 17144417329     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2332     Document Type: Article

References (50)

1. Gershenson DM, Tortolero-Luna G, Malpica A, et al. Ovarian intraepithelial neoplasia and ovarian cancer. Obstet Gynecol Clin North Am 1996;23:475-543.
2. Markman M. Intraperitoneal therapy of ovarian carcinoma. Semin Oncol 1998;25:356-60.
3. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
4. Alvarez RD, Partridge EE, Khazaeli MB, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177LU-CC49: a phase I/II study. Gynecol Oncol 1997;65:94-101.
5. Kairemo KJ. Radioimmunotherapy of solid cancer: a review. Acta Oncol 1996;35:343-55.
6. Kievit E, Pinedo HM, Schluper HM, Boven E. Addition of cisplatin improves efficiency of I-131-labelled monoclonal antibody 323/A3 in experimental human ovarian cancer. Intl J Radiol Oncology Biology Physics 2004;38:419-28.
7. Quadri SM, Malik AB, Tang XZ, Patenia R, Freedman RS, Briesendorp HM. Preclinical analysis of intraperitoneal administration of In-111-labeled human tumor reactive monoclonal IgM AC6C3-2B12. Cancer Res 1995;35(23 Suppl):5736-42s.
8. Flessner MF, Dedrick RL. Monoclonal antibody delivery to intraperitoneal tumors in rats: effects of route of administration and intraperitoneal solution osmolality. Cancer Res 1994;54:4376-84.
9. Dedrick RL, Flessner MF. Pharmacokinetic considerations on monoclonal antibodies. Immun Cancer 1989;11:429-38.
10. Flessner MF, Dedrick R. Intraperitoneal chemotherapy. In: Gokal R, Khanna R, Krediet RT, Nolph K, editors. Textbook of peritoneal dialysis. Dordrecht, Netherlands: Kluwer Academic Publishers; 2000. p. 809-27.
11. Flessner MF, Choi J, He Z, Credit K. Physiological characterization of human ovarian cancer cells in a rat model of intraperitoneal antineoplastic therapy. J Appl Physiol 2004;288:1518-26.
12. Flessner MF, Fenstermacher JD, Blasberg RG, Dedrick RL. Peritoneal absorption of macromolecules studied by quantitative autoradiography. Am J Physiol 1985;248:H26-32.
13. Flessner MF, Dedrick RL, Reynolds JC. Bidirectional peritoneal transport of immunoglobulin in rats: tissue concentration profiles. Am J Physiol 1992;263:F15-23.
14. Flessner MF. Transport of protein in the abdominal wall during intraperitoneal therapy I. Theoretical approach. Am J Physiol Gastrointest Liver Physiol 2001;281:G424-37.
15. Flessner MF. Small-solute transport across specific peritoneal tissue surfaces in the rat. J Am Soc Nephrol 1996;7:225-33.
16. Fadnes HO, Reed RK, Aukland K. Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 1985;29:176-89.
17. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990;50:4478-84.
18. Wiig H, Reed RK, Aukland K. Micropuncture measurement of interstitial fluid pressure in rat subcutis and skeletal muscle: comparison to the wick-in-needle technique. Microvasc Res 1981;21:308-19.
19. Flessner MF, Schwab A. Pressure threshold for fluid loss from the peritoneal cavity. Am J Physiol 1996;270:F377-90.
20. Fujimori K, Covell DG, Fletcher J, Weinstein J. A modeling analysis of monoclonal antibody percolation through tumors; a binding-site barrier. J Nuclear Medicine 1990;31:1191-8.
21. 2 and Fab in tumors. Cancer Res 1989;491:5656-63.
22. Dower SK, Ozato K, Segal DM. The interaction of monoclonal antibodies with MHC Class I antigens on mouse spleen cells: I. Analysis of the mechanism of binding. J Immunology 1984;132:751-8.
23. DelVecchio S, Reynolds JC, Blasberg RG, et al. Measurement of local Mr 97,000 and 250,000 protein antigen concentration in sections of human melanoma tumor using in vivo quantitative autoradiography. Cancer Res 1988;48:5475-81.
24. Flessner MF, Lofthouse J, Zakaria ER. In vivo diffusion of immunoglobulin G in muscle: effects of binding, solute exclusion, and lymphatic removal. Am J Physiol 1997;273:H2783-93.
25. Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG. A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol 1985;248:F425-35.
26. Griffon-Etiene G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999;59:3776-82.
27. Flessner MF, Lofthouse J, Zakaria EL. Improving contact area between the peritoneum and intraperitoneal therapeutic solutions. J Am Soc Nephrol 2001;12:807-13.
28. Rubin K, Sjoquist M, Gustafsson A-M, Isaksson B, Salvessen G, Reed RK. Lowering of tumoral interstitial fluid pressure by prostaglandin E1 is paralleled by an increased uptake of Cr51-EDTA. Int J Cancer 2000;86:636-43.
29. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992;52:5110-4.
30. Leunig M, Yuan F, Menger MD, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-60.
31. Flessner MF. Transport of water-soluble solutes between the peritoneal cavity and plasma in the rat. Ann Arbor, MI: University of Michigan; 1981.
32. Zakaria ER, Lofthouse J, Flessner MF. In vivo hydraulic conductivity of muscle: effects of hydrostatic pressure. Am J Physiol 1997:H2774-82.
33. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991;51:6691-4.
34. Roh HD, Boucher Y, Kalnicki S, Buchsbaum R, Bloomer WD, Jain RK. Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation exposure. Cancer Res 1991;51:6695-8.
35. Flessner MF. Osmotic barrier of the parietal peritoneum. Am J Physiol 1994;267:F861-70.
36. Zakaria ER, Lofthouse J, Flessner MF. In vivo effects of hydrostatic pressure on interstitium of abdominal wall muscle. Am J Physiol 1999;276:H517-29.
37. Twardowski ZJ, Prowam BF, Nolph KD. High volume, low frequency continuous ambulatory peritoneal dialysis. Kidney Int 1983;23:64-70.
38. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144-53.
39. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumor. I. Role of interstitial pressure and convection. Microvasc Res 1989;37:77-104.
40. Tannock IF, Lee CM, Tunggal JK, Cowan DSM, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002;8:878-84.
41. Wiig H, Tenstad O. Interstitial exclusion of positively and negatively charged IgG in rat skin and muscle. Am J Physiol Heart Circ Physiol 2001;280:H1505-12.
42. Krol A, Maresca J, Dewhirst M, Yuan F. Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery. Cancer Res 1999;59:4136-41.
43. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-51.
44. Zakaria ER, Lofthouse J, Flessner MF. Effect of intraperitoneal pressures on tissue water of the abdominal muscle. Am J Physiol Renal Physiol 2000;278:F875-85.
45. Wiig H, Lund T. Relationship between interstitial fluid volume and pressure (compliance) in hypothyroid rats. Am J Physiol Heart Circ Physiol 2001;281:H1085-92.
46. Gyenge C, Tenstad O, Wiig H. In vivo determination of steric and electrostatic exclusion of albumin in rat skin and skeletal muscle. J Physiol 2003;552:907-16.
47. Fraser JRE, Laurent TC. Hyaluronan. In: Comper WD, editors. Extracellular matrix. Amsterdam: Harwood Academic Publishers; 1996. p. 141-99.
48. Wiig H, Kolmannskog O, Tenstad O, Bert JL. Effect of charge on interstitial distribution of albumin in rat dermis in vitro. J Physiol 2003;550.2:505-14.
49. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-503.
50. Pluen A, Boucher Y, Ramanujan S, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A 2001;98:4628-33.